Tabitha Carpenter is senior vice president and head of region Europe South and West, Australia and Africa at Volvo Financial Services (VFS), the captive finance arm of the Volvo Group. Promoted to her current role in January 2020, Tabitha is responsible for leading the region and driving her team to think differently and create flexible financing solutions for the Volvo Group’s brands, dealers and customers.
A key focus of her role is to accelerate the transition to fossil-free transport solutions offered by the Volvo Group’s brands. To accomplish this, Tabitha and her team are focused on implementing innovative business models and financial solutions that eliminate potential barriers customers may face when making the switch to electric trucks and machines.
Tabitha has been with VFS for 20 years, working in various positions of increasing responsibility across the organization. Prior to her current role, Tabitha was managing director of VFS UK and Ireland, helping lead the team to exceed their business performance targets. She was also instrumental in establishing the VFS Ireland market.
Co-founder of “the” hotel investment conference for CEE. Experienced Director Of Event Management with excellent soft skills and a demonstrated history of working in the real estate industry. Skilled in project management, Microsoft Word, VIP Services, Translation, Feasibility Studies, and Hospitality Industry. Strong operations professional with a Bachelor of Science – BS focused in International Hospitality Management from Ecole hôtelière de Lausanne.
Dr. Vincent Angelico is a co-founder of Accorto Regulatory Solutions and serves as its Chief Science Officer. In this role, Vince spends most of his time working with clients to formulate cost effective and successful regulatory strategies that meet client and FDA expectations. Prior to joining Accorto, Vince was a senior executive at Blackbriar Regulatory Services, where he provided scientific and regulatory consulting to several alternative nicotine products companies and developed the regulatory strategy for Avail Vapor LLC, which ultimately submitted some of the few pre-market applications that the FDA did not reject in this constantly changing newly regulated market. Vince developed his professional career working in the in the pharmaceutical industry, starting out as research and development chemist at Merck & Co Pharmaceuticals. While at Merck, Vince helped develop products in the new drug pipeline and moved through the ranks to become a product development team leader. His work led to regulatory filings on the notable cholesterol regulating drug ZOCOR™ (simvastatin). Vince later worked for the German based pharmaceutical company Boehringer Ingelheim (BI), where he was assigned to their active ingredient manufacturing site in Petersburg Virginia. Vince served in several different leadership roles for BI before ultimately becoming the Director of Manufacturing Operations in 2012. Vince holds a BS in Chemistry from Virginia Commonwealth University and a Ph.D. in Analytical Chemistry from the University of Arizona.
Eric Gotting represents Keller and Heckman’s clients in litigation and related matters, specializing in complex civil and appellate matters, internal investigations, and regulatory compliance. With an extensive background in environmental and FDA law, he has expanded his practice over the years to cover many of Keller and Heckman’s industry sectors and regulatory areas, including tobacco and e-vapor. Eric is a former Am Law 50 litigation partner and U.S. Department of Justice, Civil Division, Trial Attorney. Eric’s practice spans a broad range of legal issues, including administrative and constitutional law, agency enforcement actions, toxic torts, product liability, general business litigation, and regulatory advice. He works with a diverse set of industries, including chemicals, plastics, pesticides, fuels and pipelines, food and packaging, consumer goods, telecommunications, and e-cigarettes. As a litigator, Eric has tried cases to verdict and argued appeals before federal and state courts across the country. His experience includes class actions, mass tort litigation, AAA arbitrations, and agency proceedings. Eric has also litigated challenges to federal and state statutes, regulations, and orders, including PMTA marketing denial orders. He has particular expertise involving the Administrative Procedure Act (APA), the Dormant Commerce Clause, the First Amendment, the Due Process Clause, and federal preemption. He has also filed amicus briefs in litigation involving regulatory issues facing a variety of industry sectors, including on behalf of the e-vapor industry.
Keith Kennedy is a subject matter expert in eCOA/ePRO, eConsent, tele visits, wearables and other decentralized clinical trial tools. For over 15 years, Keith has consulted pharmaceutical, medical device and biotech companies on the best strategy to collect patient facing data in clinical trials in order to maximize patient compliance, increase data quality and decrease patient burden. A distinguished career in healthcare sales leadership, talent development and product education.
Inès is an Innovation Analyst at HSBC working with Large Language Models and Generative AI. The focus of her work is exploring the potential of Generative AI to derive insights and create new ways to approach and solve problems. She uses her expertise to help her colleagues to better understand Generative AI and empower them to utilise these tools. In her spare time, Inès enjoys exploring her creative side through arts and crafts.
